Dicerna

The delivery approach has gained traction in recent years and is being explored by a number of RNA drug firms.

Dicerna's new RNAi triggers and conjugate technology are entirely proprietary and fall outside of intellectual property held by other organizations, according to a company official.

NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals last week reported its third-quarter financial results, posting higher losses amid increased spending on its drug-development programs.
Dicerna's net loss for the period rose to $11.2 million from $4.5 million the year before.

NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals this month confirmed previous guidance on its two drug candidates, the solid tumor therapy DCR-MYC and the primary hyperoxaluria 1 (PH1) treatment DCR-PH1, stating that both agents remain on track to enter new clinical trials later this year and in 2

Key RNAi Drugs in the Clinic

Premium

NEW YORK (GenomeWeb) – With more interest from industry and investors than ever before, the RNAi therapeutics field has a record number of drug candidates in human testing for indications ranging from viral disease to cancer to skin disorders.

NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals this week announced preclinical data showing that its investigational primary hyperoxaluria type 1 (PH1) therapy DCR-PH1 could silence expression of its target by as much as 97 percent in a mouse model of the disease.

NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals this week reported its first-quarter financial results, posting a jump in its net loss due to higher costs associated with drug development and its recently completed initial public offering.

NEW YORK (GenomeWeb) – Amid a recent downturn among biotechnology stocks, shares of the top eight publicly traded RNAi and microRNA drug developers have fared particularly poorly, shedding an average of 37 percent of their value from their year-to-date highs.

Dicerna Pharmaceuticals this week announced that it has begun dosing patients in a Phase I trial of its RNAi cancer treatment DCR-MYC, formerly known as DCR-M1711.

Officials from newly public Dicerna Pharmaceuticals last week provided an update on the company's two pipeline programs, offering some details on the planned Phase I program for its lead cancer therapeutic, as well as timing on when a new drug candidate will be named.

Pages

An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.

The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.

In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.

Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.